| trial |
intervention |
phase |
identifier |
| A Randomised, Controlled, Phase 1 Study to Evaluate the Safety and Immunogenicity of a Candidate Adjuvanted Recombinant Protein SARS-COV-2 Vaccine in Healthy Adult Subjects (edit) |
COVAX-19 (edit) |
第I相試験 (edit) |
NCT04453852 |
| An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19 (edit) |
ヒドロキシクロロキン (edit) |
第III相試験 (edit) |
NCT04434248 |
| An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19 (edit) |
ヒドロキシクロロキン (edit) |
第II相試験 (edit) |
NCT04434248 |
| An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19 (edit) |
クロロキン (edit) |
第III相試験 (edit) |
NCT04434248 |
| An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19 (edit) |
クロロキン (edit) |
第II相試験 (edit) |
NCT04434248 |
| An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19 (edit) |
ロピナビル (edit) |
第III相試験 (edit) |
NCT04434248 |
| An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19 (edit) |
ロピナビル (edit) |
第II相試験 (edit) |
NCT04434248 |
| An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19 (edit) |
リトナビル (edit) |
第III相試験 (edit) |
NCT04434248 |
| An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19 (edit) |
リトナビル (edit) |
第II相試験 (edit) |
NCT04434248 |
| Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older (edit) |
エラソメラン (edit) |
第II相試験 (edit) |
NCT04405076 |
| Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19) (edit) |
|
第III相試験 (edit) |
NCT04380519 |
| Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19) (edit) |
|
第II相試験 (edit) |
NCT04380519 |
| Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults (edit) |
トジナメラン (edit) |
第III相試験 (edit) |
NCT04368728 |
| Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults (edit) |
トジナメラン (edit) |
第II相試験 (edit) |
NCT04368728 |
| Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults (edit) |
トジナメラン (edit) |
第I相試験 (edit) |
NCT04368728 |
| Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity (edit) |
ブデソニド (edit) |
第III相試験 (edit) |
NCT04361474 |
| COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1 (edit) |
ニボルマブ (edit) |
第II相試験 (edit) |
NCT04356508 |
| Interferon Beta 1a in Hospitalized COVID-19 Patients (edit) |
インターフェロン (edit) |
第IV相試験 (edit) |
NCT04350671 |
| Interferon Beta 1a in Hospitalized COVID-19 Patients (edit) |
アボネックス (edit) |
第IV相試験 (edit) |
NCT04350671 |
| Interferon Beta 1a in Hospitalized COVID-19 Patients (edit) |
ヒドロキシクロロキン (edit) |
第IV相試験 (edit) |
NCT04350671 |
| Interferon Beta 1a in Hospitalized COVID-19 Patients (edit) |
ロピナビル (edit) |
第IV相試験 (edit) |
NCT04350671 |
| Interferon Beta 1a in Hospitalized COVID-19 Patients (edit) |
リトナビル (edit) |
第IV相試験 (edit) |
NCT04350671 |
| Treatment of SARS Caused by COVID-19 With Ruxolitinib (edit) |
ルキソリチニブ (edit) |
第II相試験 (edit) |
NCT04334044 |
| Treatment of SARS Caused by COVID-19 With Ruxolitinib (edit) |
ルキソリチニブ (edit) |
第I相試験 (edit) |
NCT04334044 |
| Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection (edit) |
クロロキン (edit) |
第II相試験 (edit) |
NCT04333914 |
| Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection (edit) |
Chloroquine diphosphate bearing dextran nanoparticles augmented drug delivery and overwhelmed drug resistance in Plasmodium falciparum parasites (edit) |
第II相試験 (edit) |
NCT04333914 |
| Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection (edit) |
ニボルマブ (edit) |
第II相試験 (edit) |
NCT04333914 |
| CROWN CORONATION: Chloroquine RepurpOsing to healthWorkers for Novel CORONAvirus mitigaTION (edit) |
ヒドロキシクロロキン (edit) |
第II相試験 (edit) |
NCT04333732 |
| CROWN CORONATION: Chloroquine RepurpOsing to healthWorkers for Novel CORONAvirus mitigaTION (edit) |
クロロキン (edit) |
第II相試験 (edit) |
NCT04333732 |
| CROWN CORONATION: Chloroquine RepurpOsing to healthWorkers for Novel CORONAvirus mitigaTION (edit) |
Chloroquine diphosphate bearing dextran nanoparticles augmented drug delivery and overwhelmed drug resistance in Plasmodium falciparum parasites (edit) |
第II相試験 (edit) |
NCT04333732 |
| Hydroxychloroquine in Outpatient Adults With COVID-19 (edit) |
ヒドロキシクロロキン (edit) |
第I相試験 (edit) |
NCT04333654 |
| Chloroquine for Mild Symptomatic and Asymptomatic COVID-19 (edit) |
クロロキン (edit) |
第III相試験 (edit) |
NCT04333628 |
| Chloroquine for Mild Symptomatic and Asymptomatic COVID-19 (edit) |
クロロキン (edit) |
第II相試験 (edit) |
NCT04333628 |
| Chloroquine for Mild Symptomatic and Asymptomatic COVID-19 (edit) |
Chloroquine diphosphate bearing dextran nanoparticles augmented drug delivery and overwhelmed drug resistance in Plasmodium falciparum parasites (edit) |
第III相試験 (edit) |
NCT04333628 |
| Chloroquine for Mild Symptomatic and Asymptomatic COVID-19 (edit) |
Chloroquine diphosphate bearing dextran nanoparticles augmented drug delivery and overwhelmed drug resistance in Plasmodium falciparum parasites (edit) |
第II相試験 (edit) |
NCT04333628 |
| Application of Desferal to Treat COVID-19 (edit) |
デフェロキサミン (edit) |
第II相試験 (edit) |
NCT04333550 |
| Application of Desferal to Treat COVID-19 (edit) |
デフェロキサミン (edit) |
第I相試験 (edit) |
NCT04333550 |
| Piclidenoson for Treatment of COVID-19 (edit) |
piclidenoson (edit) |
第II相試験 (edit) |
NCT04333472 |
| OPEN LABEL, RANDOMIZED PHASE II/III STUDY OF IFX-1 IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA (edit) |
|
第III相試験 (edit) |
NCT04333420 |
| OPEN LABEL, RANDOMIZED PHASE II/III STUDY OF IFX-1 IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA (edit) |
|
第II相試験 (edit) |
NCT04333420 |
| Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS (edit) |
|
第II相試験 (edit) |
NCT04333368 |
| Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS (edit) |
|
第I相試験 (edit) |
NCT04333368 |
| Safety in Convalescent Plasma Transfusion to COVID-19 (edit) |
|
第I相試験 (edit) |
NCT04333355 |
| Study Testing Convalescent Plasma vs Best Supportive Care (edit) |
|
第I相試験 (edit) |
NCT04333251 |
| Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers (edit) |
ヒドロキシクロロキン (edit) |
第II相試験 (edit) |
NCT04333225 |
| Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease (edit) |
ヒドロキシクロロキン (edit) |
第III相試験 (edit) |
NCT04332991 |
| Convalescent Plasma for Patients With COVID-19: A Randomized, Open Label, Parallel, Controlled Clinical Study (edit) |
ヒドロキシクロロキン (edit) |
第III相試験 (edit) |
NCT04332835 |
| Convalescent Plasma for Patients With COVID-19: A Randomized, Open Label, Parallel, Controlled Clinical Study (edit) |
ヒドロキシクロロキン (edit) |
第II相試験 (edit) |
NCT04332835 |
| Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial (edit) |
ACE阻害薬 (edit) |
第III相試験 (edit) |
NCT04332666 |
| Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial (edit) |
ACE阻害薬 (edit) |
第II相試験 (edit) |
NCT04332666 |
| Convalescent Plasma for Patients With COVID-19: A Pilot Study (edit) |
|
第II相試験 (edit) |
NCT04332380 |
| Azithromycin for COVID-19 Treatment in Outpatients Nationwide (edit) |
アジスロマイシン (edit) |
第III相試験 (edit) |
NCT04332107 |
| Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19 (edit) |
アジスロマイシン (edit) |
第II相試験 (edit) |
NCT04332094 |
| Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19 (edit) |
ヒドロキシクロロキン (edit) |
第II相試験 (edit) |
NCT04332094 |
| Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19 (edit) |
トシリズマブ (edit) |
第II相試験 (edit) |
NCT04332094 |
| Mild COVID-19 Peginterferon Lambda (edit) |
|
第II相試験 (edit) |
NCT04331899 |
| Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic (edit) |
ヒドロキシクロロキン (edit) |
第III相試験 (edit) |
NCT04331834 |
| Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Tocilizumab Trial - CORIMUNO-19 - TOCI (CORIMUNO-TOCI) (edit) |
トシリズマブ (edit) |
第II相試験 (edit) |
NCT04331808 |
| Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis (edit) |
トシリズマブ (edit) |
第II相試験 (edit) |
NCT04331795 |
| Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS (edit) |
|
第II相試験 (edit) |
NCT04331613 |
| Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS (edit) |
|
第I相試験 (edit) |
NCT04331613 |
| ChloroQUine As antiviRal treAtmeNT In coroNavirus infEction 2020 (edit) |
クロロキン (edit) |
第IV相試験 (edit) |
NCT04331600 |
| ChloroQUine As antiviRal treAtmeNT In coroNavirus infEction 2020 (edit) |
Chloroquine diphosphate bearing dextran nanoparticles augmented drug delivery and overwhelmed drug resistance in Plasmodium falciparum parasites (edit) |
第IV相試験 (edit) |
NCT04331600 |
| Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19 (edit) |
formoterol fumarate (edit) |
第III相試験 (edit) |
NCT04331470 |
| Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19 (edit) |
formoterol fumarate (edit) |
第II相試験 (edit) |
NCT04331470 |
| Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19 (edit) |
レバミゾール (edit) |
第III相試験 (edit) |
NCT04331470 |
| Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19 (edit) |
レバミゾール (edit) |
第II相試験 (edit) |
NCT04331470 |
| Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19 (edit) |
ブデソニド (edit) |
第III相試験 (edit) |
NCT04331470 |
| Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19 (edit) |
ブデソニド (edit) |
第II相試験 (edit) |
NCT04331470 |
| Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19 (edit) |
クロロキン (edit) |
第III相試験 (edit) |
NCT04331470 |
| Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19 (edit) |
クロロキン (edit) |
第II相試験 (edit) |
NCT04331470 |
| Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19 (edit) |
ロピナビル (edit) |
第III相試験 (edit) |
NCT04331470 |
| Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19 (edit) |
ロピナビル (edit) |
第II相試験 (edit) |
NCT04331470 |
| Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19 (edit) |
リトナビル (edit) |
第III相試験 (edit) |
NCT04331470 |
| Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19 (edit) |
リトナビル (edit) |
第II相試験 (edit) |
NCT04331470 |
| Protective Role of Inhaled Steroids for Covid-19 Infection (edit) |
ブデソニド (edit) |
第III相試験 (edit) |
NCT04331054 |
| Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial (edit) |
ロピナビル (edit) |
第II相試験 (edit) |
NCT04330690 |
| Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial (edit) |
リトナビル (edit) |
第II相試験 (edit) |
NCT04330690 |
| Treatment of COVID-19 Patients With Anti-interleukin Drugs (edit) |
siltuximab (edit) |
第IV相試験 (edit) |
NCT04330638 |
| Treatment of COVID-19 Patients With Anti-interleukin Drugs (edit) |
アナキンラ (edit) |
第IV相試験 (edit) |
NCT04330638 |
| A Trial of Ciclesonide in Adults With Mild COVID-19 (edit) |
ヒドロキシクロロキン (edit) |
第II相試験 (edit) |
NCT04330586 |
| A Trial of Ciclesonide in Adults With Mild COVID-19 (edit) |
シクレソニド (edit) |
第II相試験 (edit) |
NCT04330586 |
| Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection (edit) |
ヤヌスキナーゼ阻害薬 (edit) |
第IV相試験 (edit) |
NCT04330495 |
| Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection (edit) |
ヒドロキシクロロキン (edit) |
第IV相試験 (edit) |
NCT04330495 |
| Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial) (edit) |
ヒドロキシクロロキン (edit) |
第III相試験 (edit) |
NCT04330144 |
| The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine) (edit) |
ヒドロキシクロロキン (edit) |
第II相試験 (edit) |
NCT04329923 |
| Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19 (edit) |
ヒドロキシクロロキン (edit) |
第II相試験 (edit) |
NCT04329832 |
| Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 Pneumonia (edit) |
プレドニゾロン (edit) |
第II相試験 (edit) |
NCT04329650 |
| Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 Pneumonia (edit) |
酢酸メチルプレドニゾロン (edit) |
第II相試験 (edit) |
NCT04329650 |
| Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 Pneumonia (edit) |
酢酸プレドニゾロン (edit) |
第II相試験 (edit) |
NCT04329650 |
| Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 Pneumonia (edit) |
methylprednisolone hemisuccinate (edit) |
第II相試験 (edit) |
NCT04329650 |
| Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 Pneumonia (edit) |
prednisolone 21-phosphate (edit) |
第II相試験 (edit) |
NCT04329650 |
| Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 Pneumonia (edit) |
prednisolone hemisuccinate (edit) |
第II相試験 (edit) |
NCT04329650 |
| Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 Pneumonia (edit) |
siltuximab (edit) |
第II相試験 (edit) |
NCT04329650 |
| Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 Pneumonia (edit) |
メチルプレドニゾロン (edit) |
第II相試験 (edit) |
NCT04329650 |
| Hydroxychloroquine to Prevent Covid19 Pneumonia (ALBERTA HOPE-Covid19) (edit) |
ヒドロキシクロロキン (edit) |
第III相試験 (edit) |
NCT04329611 |
| Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19 (edit) |
ヒドロキシクロロキン (edit) |
第I相試験 (edit) |
NCT04329572 |
| EPICOS Clinical Trial for the Prevention of Infection in Healthcare Personnel (edit) |
テノフォビル (edit) |
第III相試験 (edit) |
NCT04329520 |
| EPICOS Clinical Trial for the Prevention of Infection in Healthcare Personnel (edit) |
ヒドロキシクロロキン (edit) |
第III相試験 (edit) |
NCT04329520 |
| EPICOS Clinical Trial for the Prevention of Infection in Healthcare Personnel (edit) |
エムトリシタビン (edit) |
第III相試験 (edit) |
NCT04329520 |
| ACE Inhibitors or ARBs Discontinuation in Context of SARS-CoV-2 Pandemia (edit) |
ACE阻害薬 (edit) |
第III相試験 (edit) |
NCT04329195 |
| Hydroxychloroquine for COVID-19 PEP (edit) |
アスコルビン酸 (edit) |
第I相試験 (edit) |
NCT04328961 |
| Hydroxychloroquine for COVID-19 PEP (edit) |
ヒドロキシクロロキン (edit) |
第I相試験 (edit) |
NCT04328961 |
| The Vietnam Chloroquine Treatment on COVID-19 (edit) |
クロロキン (edit) |
第II相試験 (edit) |
NCT04328493 |
| The Vietnam Chloroquine Treatment on COVID-19 (edit) |
Chloroquine diphosphate bearing dextran nanoparticles augmented drug delivery and overwhelmed drug resistance in Plasmodium falciparum parasites (edit) |
第II相試験 (edit) |
NCT04328493 |
| REDUCING HEALTH CARE WORKERS ABSENTEEISM IN SARS-CoV-2 PANDEMIC THROUGH BACILLUS CALMETTE-GUÉRIN VACCINATION, A RANDOMIZED CONTROLLED TRIAL (edit) |
BCG (edit) |
第III相試験 (edit) |
NCT04328441 |
| Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers (edit) |
ヒドロキシクロロキン (edit) |
第III相試験 (edit) |
NCT04328285 |
| Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers (edit) |
ロピナビル (edit) |
第III相試験 (edit) |
NCT04328285 |
| Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers (edit) |
リトナビル (edit) |
第III相試験 (edit) |
NCT04328285 |
| Effectiveness of Hydroxychloroquine in Covid-19 Patients (edit) |
ヒドロキシクロロキン (edit) |
第III相試験 (edit) |
NCT04328272 |
| Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive randoMizED Clinical Trial During the COVID-19 Pandemic (COVID MED Trial) (edit) |
coal tar pitch volatiles (edit) |
第III相試験 (edit) |
NCT04328012 |
| Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive randoMizED Clinical Trial During the COVID-19 Pandemic (COVID MED Trial) (edit) |
coal tar pitch volatiles (edit) |
第II相試験 (edit) |
NCT04328012 |
| Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive randoMizED Clinical Trial During the COVID-19 Pandemic (COVID MED Trial) (edit) |
ロサルタン (edit) |
第III相試験 (edit) |
NCT04328012 |
| Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive randoMizED Clinical Trial During the COVID-19 Pandemic (COVID MED Trial) (edit) |
ロサルタン (edit) |
第II相試験 (edit) |
NCT04328012 |
| Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive randoMizED Clinical Trial During the COVID-19 Pandemic (COVID MED Trial) (edit) |
ヒドロキシクロロキン (edit) |
第III相試験 (edit) |
NCT04328012 |
| Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive randoMizED Clinical Trial During the COVID-19 Pandemic (COVID MED Trial) (edit) |
ヒドロキシクロロキン (edit) |
第II相試験 (edit) |
NCT04328012 |
| Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive randoMizED Clinical Trial During the COVID-19 Pandemic (COVID MED Trial) (edit) |
ロピナビル (edit) |
第III相試験 (edit) |
NCT04328012 |
| Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive randoMizED Clinical Trial During the COVID-19 Pandemic (COVID MED Trial) (edit) |
ロピナビル (edit) |
第II相試験 (edit) |
NCT04328012 |
| Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive randoMizED Clinical Trial During the COVID-19 Pandemic (COVID MED Trial) (edit) |
リトナビル (edit) |
第III相試験 (edit) |
NCT04328012 |
| Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive randoMizED Clinical Trial During the COVID-19 Pandemic (COVID MED Trial) (edit) |
リトナビル (edit) |
第II相試験 (edit) |
NCT04328012 |
| Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19 (edit) |
|
第III相試験 (edit) |
NCT04327505 |
| Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19 (edit) |
|
第II相試験 (edit) |
NCT04327505 |
| COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III (edit) |
酢酸デキサメタゾン (edit) |
第III相試験 (edit) |
NCT04327401 |
| COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III (edit) |
シクロホスファミド (edit) |
第III相試験 (edit) |
NCT04327401 |
| Sarilumab COVID-19 (edit) |
|
第III相試験 (edit) |
NCT04327388 |
| Sarilumab COVID-19 (edit) |
|
第II相試験 (edit) |
NCT04327388 |
| BCG Vaccination to Protect Healthcare Workers Against COVID-19 (edit) |
BCG (edit) |
第III相試験 (edit) |
NCT04327206 |
| Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC) (edit) |
サルグラモスチム (edit) |
第IV相試験 (edit) |
NCT04326920 |
| The GReek Study in the Effects of Colchicine in Covid-19 (edit) |
gloriosine (edit) |
第IV相試験 (edit) |
NCT04326790 |
| COVIDL1: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection (edit) |
|
第III相試験 (edit) |
NCT04326426 |
| Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection (edit) |
|
第I相試験 (edit) |
NCT04326036 |
| Hydroxychloroquine Versus Placebo in Patients Presenting COVID-19 Infection and at Risk of Secondary Complication: a Prospective, Multicentre, Randomised, Double-blind Study (edit) |
ヒドロキシクロロキン (edit) |
第III相試験 (edit) |
NCT04325893 |
| Convalescent Plasma to Limit Coronavirus Associated Complications (edit) |
|
第II相試験 (edit) |
NCT04325672 |
| Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection (edit) |
ナプロキセン (edit) |
第III相試験 (edit) |
NCT04325633 |
| Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19 (edit) |
酢酸デキサメタゾン (edit) |
第IV相試験 (edit) |
NCT04325061 |
| Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19 (edit) |
シクロホスファミド (edit) |
第IV相試験 (edit) |
NCT04325061 |
| A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19 (edit) |
サルグラモスチム (edit) |
第II相試験 (edit) |
NCT04324996 |
| A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19 (edit) |
サルグラモスチム (edit) |
第I相試験 (edit) |
NCT04324996 |
| A Study of a Candidate COVID-19 Vaccine (COV001) (edit) |
AZD1222 (edit) |
第I相試験 (edit) |
NCT04324606 |
| A Study of a Candidate COVID-19 Vaccine (COV001) (edit) |
AZD1222 (edit) |
第II相試験 (edit) |
NCT04324606 |
| Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial (edit) |
クロロキン (edit) |
第III相試験 (edit) |
NCT04324463 |
| Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial (edit) |
Chloroquine diphosphate bearing dextran nanoparticles augmented drug delivery and overwhelmed drug resistance in Plasmodium falciparum parasites (edit) |
第III相試験 (edit) |
NCT04324463 |
| Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI (edit) |
|
第II相試験 (edit) |
NCT04324073 |
| Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI (edit) |
|
第III相試験 (edit) |
NCT04324073 |
| Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection. (edit) |
アナキンラ (edit) |
第III相試験 (edit) |
NCT04324021 |
| Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection. (edit) |
アナキンラ (edit) |
第II相試験 (edit) |
NCT04324021 |
| Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19 (edit) |
|
第II相試験 (edit) |
NCT04323800 |
| Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death (edit) |
ヒドロキシクロロキン (edit) |
第I相試験 (edit) |
NCT04323631 |
| Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome (edit) |
プレドニゾロン (edit) |
第III相試験 (edit) |
NCT04323592 |
| Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome (edit) |
プレドニゾロン (edit) |
第II相試験 (edit) |
NCT04323592 |
| Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome (edit) |
酢酸メチルプレドニゾロン (edit) |
第III相試験 (edit) |
NCT04323592 |
| Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome (edit) |
酢酸メチルプレドニゾロン (edit) |
第II相試験 (edit) |
NCT04323592 |
| Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome (edit) |
酢酸プレドニゾロン (edit) |
第III相試験 (edit) |
NCT04323592 |
| Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome (edit) |
酢酸プレドニゾロン (edit) |
第II相試験 (edit) |
NCT04323592 |
| Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome (edit) |
methylprednisolone hemisuccinate (edit) |
第III相試験 (edit) |
NCT04323592 |
| Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome (edit) |
methylprednisolone hemisuccinate (edit) |
第II相試験 (edit) |
NCT04323592 |
| Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome (edit) |
prednisolone 21-phosphate (edit) |
第III相試験 (edit) |
NCT04323592 |
| Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome (edit) |
prednisolone 21-phosphate (edit) |
第II相試験 (edit) |
NCT04323592 |
| Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome (edit) |
prednisolone hemisuccinate (edit) |
第III相試験 (edit) |
NCT04323592 |
| Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome (edit) |
prednisolone hemisuccinate (edit) |
第II相試験 (edit) |
NCT04323592 |
| Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome (edit) |
メチルプレドニゾロン (edit) |
第III相試験 (edit) |
NCT04323592 |
| Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome (edit) |
メチルプレドニゾロン (edit) |
第II相試験 (edit) |
NCT04323592 |
| Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus (edit) |
ヒドロキシクロロキン (edit) |
第III相試験 (edit) |
NCT04323345 |
| Traditional Chinese Medicine for Severe COVID-19 (edit) |
|
第III相試験 (edit) |
NCT04323332 |
| Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19 (edit) |
非ステロイド性抗炎症薬 (edit) |
第IV相試験 (edit) |
NCT04323228 |
| Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure (edit) |
|
第II相試験 (edit) |
NCT04322773 |
| コルヒチンコロナウイルスSARS-CoV2試験 (edit) |
コルヒチン (edit) |
第III相試験 (edit) |
NCT04322682 |
| Colchicine Efficacy in COVID-19 Pneumonia (edit) |
gloriosine (edit) |
第II相試験 (edit) |
NCT04322565 |
| Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalized Patients With COVID-19 (edit) |
ヒドロキシクロロキン (edit) |
第IV相試験 (edit) |
NCT04322396 |
| Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalized Patients With COVID-19 (edit) |
クロロキン (edit) |
第IV相試験 (edit) |
NCT04322396 |
| Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalized Patients With COVID-19 (edit) |
Chloroquine diphosphate bearing dextran nanoparticles augmented drug delivery and overwhelmed drug resistance in Plasmodium falciparum parasites (edit) |
第IV相試験 (edit) |
NCT04322396 |
| Escin in Patients With Covid-19 Infection (edit) |
|
第III相試験 (edit) |
NCT04322344 |
| Escin in Patients With Covid-19 Infection (edit) |
|
第II相試験 (edit) |
NCT04322344 |
| Safety and Efficacy of Hydroxychloroquine Associated With Azythromycin in SARS-Cov-2 Virus (edit) |
ヒドロキシクロロキン (edit) |
第III相試験 (edit) |
NCT04322123 |
| Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients (edit) |
ヤヌスキナーゼ阻害薬 (edit) |
第II相試験 (edit) |
NCT04321993 |
| Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients (edit) |
ヒドロキシクロロキン (edit) |
第II相試験 (edit) |
NCT04321993 |
| Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients (edit) |
ロピナビル (edit) |
第II相試験 (edit) |
NCT04321993 |
| Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients (edit) |
リトナビル (edit) |
第II相試験 (edit) |
NCT04321993 |
| The Efficacy of Different Anti-viral Drugs in (Severe Acute Respiratory Syndrome-Corona Virus-2) SARS-CoV-2 (edit) |
抗ウイルス剤 (edit) |
第III相試験 (edit) |
NCT04321616 |
| The Efficacy of Different Anti-viral Drugs in (Severe Acute Respiratory Syndrome-Corona Virus-2) SARS-CoV-2 (edit) |
抗ウイルス剤 (edit) |
第II相試験 (edit) |
NCT04321616 |
| The Efficacy of Different Anti-viral Drugs in (Severe Acute Respiratory Syndrome-Corona Virus-2) SARS-CoV-2 (edit) |
ヒドロキシクロロキン (edit) |
第III相試験 (edit) |
NCT04321616 |
| The Efficacy of Different Anti-viral Drugs in (Severe Acute Respiratory Syndrome-Corona Virus-2) SARS-CoV-2 (edit) |
ヒドロキシクロロキン (edit) |
第II相試験 (edit) |
NCT04321616 |
| Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II) (edit) |
ヒドロキシクロロキン (edit) |
第III相試験 (edit) |
NCT04321278 |
| COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir (edit) |
ロピナビル (edit) |
第III相試験 (edit) |
NCT04321174 |
| COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir (edit) |
リトナビル (edit) |
第III相試験 (edit) |
NCT04321174 |
| The Impact of Camostat Mesilate on COVID-19 Infection (edit) |
gabexate (edit) |
第II相試験 (edit) |
NCT04321096 |
| The Impact of Camostat Mesilate on COVID-19 Infection (edit) |
gabexate (edit) |
第I相試験 (edit) |
NCT04321096 |
| A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia (edit) |
|
第III相試験 (edit) |
NCT04320615 |
| Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study. (edit) |
抗ウイルス剤 (edit) |
第III相試験 (edit) |
NCT04320277 |
| Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study. (edit) |
リトナビル (edit) |
第III相試験 (edit) |
NCT04320277 |
| Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff (edit) |
インターフェロン (edit) |
第III相試験 (edit) |
NCT04320238 |
| Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff (edit) |
thymalfasin (edit) |
第III相試験 (edit) |
NCT04320238 |
| A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure (edit) |
|
第I相試験 (edit) |
NCT04319731 |
| Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19) (edit) |
ヒドロキシクロロキン (edit) |
第III相試験 (edit) |
NCT04318444 |
| Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19) (edit) |
ヒドロキシクロロキン (edit) |
第II相試験 (edit) |
NCT04318444 |
| Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial) (edit) |
ヒドロキシクロロキン (edit) |
第III相試験 (edit) |
NCT04318015 |
| Tocilizumab in COVID-19 Pneumonia (TOCIVID-19) (edit) |
トシリズマブ (edit) |
第II相試験 (edit) |
NCT04317092 |
| CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment (edit) |
|
第III相試験 (edit) |
NCT04317040 |
| Norwegian Coronavirus Disease 2019 Study (edit) |
ヒドロキシクロロキン (edit) |
第IV相試験 (edit) |
NCT04316377 |
| Norwegian Coronavirus Disease 2019 Study (edit) |
クロロキン (edit) |
第IV相試験 (edit) |
NCT04316377 |
| Norwegian Coronavirus Disease 2019 Study (edit) |
Chloroquine diphosphate bearing dextran nanoparticles augmented drug delivery and overwhelmed drug resistance in Plasmodium falciparum parasites (edit) |
第IV相試験 (edit) |
NCT04316377 |
| NestCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia (edit) |
|
第I相試験 (edit) |
NCT04315987 |
| Trial of Treatments for COVID-19 in Hospitalized Adults (edit) |
インターフェロン (edit) |
第III相試験 (edit) |
NCT04315948 |
| Trial of Treatments for COVID-19 in Hospitalized Adults (edit) |
アボネックス (edit) |
第III相試験 (edit) |
NCT04315948 |
| Trial of Treatments for COVID-19 in Hospitalized Adults (edit) |
ヒドロキシクロロキン (edit) |
第III相試験 (edit) |
NCT04315948 |
| Trial of Treatments for COVID-19 in Hospitalized Adults (edit) |
ロピナビル (edit) |
第III相試験 (edit) |
NCT04315948 |
| Trial of Treatments for COVID-19 in Hospitalized Adults (edit) |
リトナビル (edit) |
第III相試験 (edit) |
NCT04315948 |
| Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial) (edit) |
ヒドロキシクロロキン (edit) |
第III相試験 (edit) |
NCT04315896 |
| Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 (edit) |
|
第III相試験 (edit) |
NCT04315298 |
| Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 (edit) |
|
第II相試験 (edit) |
NCT04315298 |
| Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells (edit) |
|
第I相試験 (edit) |
NCT04313322 |
| A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2 (edit) |
パラセタモール (edit) |
第II相試験 (edit) |
NCT04313023 |
| The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection (edit) |
パラセタモール (edit) |
第II相試験 (edit) |
NCT04312997 |
| NO Prevention of COVID-19 for Healthcare Providers (edit) |
一酸化窒素 (edit) |
第II相試験 (edit) |
NCT04312243 |
| Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization (edit) |
ロサルタン (edit) |
第II相試験 (edit) |
NCT04312009 |
| Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress (edit) |
フェントラミン (edit) |
第II相試験 (edit) |
NCT04311697 |
| Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization (edit) |
ロサルタン (edit) |
第II相試験 (edit) |
NCT04311177 |
| Yinhu Qingwen Granula for the Treatment of Severe CoVID-19 (edit) |
|
第III相試験 (edit) |
NCT04310865 |
| Yinhu Qingwen Granula for the Treatment of Severe CoVID-19 (edit) |
|
第II相試験 (edit) |
NCT04310865 |
| Tetrandrine Tablets Used in the Treatment of COVID-19 (edit) |
|
第IV相試験 (edit) |
NCT04308317 |
| Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19) (edit) |
ヒドロキシクロロキン (edit) |
第II相試験 (edit) |
NCT04307693 |
| Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19) (edit) |
ロピナビル (edit) |
第II相試験 (edit) |
NCT04307693 |
| Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19) (edit) |
リトナビル (edit) |
第II相試験 (edit) |
NCT04307693 |
| Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19 (edit) |
一酸化窒素 (edit) |
第II相試験 (edit) |
NCT04305457 |
| A Pilot Study of Sildenafil in COVID-19 (edit) |
クエン酸 (edit) |
第III相試験 (edit) |
NCT04304313 |
| A Pilot Study of Sildenafil in COVID-19 (edit) |
sildenafil citrate (edit) |
第III相試験 (edit) |
NCT04304313 |
| A Pilot Study of Sildenafil in COVID-19 (edit) |
クエン酸三ナトリウム (edit) |
第III相試験 (edit) |
NCT04304313 |
| Treatment of Mild Cases and Chemoprophylaxis of Contacts as Prevention of the COVID-19 Epidemic (edit) |
抗ウイルス剤 (edit) |
第III相試験 (edit) |
NCT04304053 |
| Treatment of Mild Cases and Chemoprophylaxis of Contacts as Prevention of the COVID-19 Epidemic (edit) |
クロロキン (edit) |
第III相試験 (edit) |
NCT04304053 |
| Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Chloroquin for Treatment of COVID19 : A Randomized Control Trial (edit) |
オセルタミビル (edit) |
第III相試験 (edit) |
NCT04303299 |
| Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Chloroquin for Treatment of COVID19 : A Randomized Control Trial (edit) |
ダルナビル (edit) |
第III相試験 (edit) |
NCT04303299 |
| Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Chloroquin for Treatment of COVID19 : A Randomized Control Trial (edit) |
クロロキン (edit) |
第III相試験 (edit) |
NCT04303299 |
| Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Chloroquin for Treatment of COVID19 : A Randomized Control Trial (edit) |
ロピナビル (edit) |
第III相試験 (edit) |
NCT04303299 |
| Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Chloroquin for Treatment of COVID19 : A Randomized Control Trial (edit) |
リトナビル (edit) |
第III相試験 (edit) |
NCT04303299 |
| Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Chloroquin for Treatment of COVID19 : A Randomized Control Trial (edit) |
Chloroquine diphosphate bearing dextran nanoparticles augmented drug delivery and overwhelmed drug resistance in Plasmodium falciparum parasites (edit) |
第III相試験 (edit) |
NCT04303299 |
| Safety and Immunity of Covid-19 aAPC Vaccine (edit) |
|
第I相試験 (edit) |
NCT04299724 |
| Stem Cell Educator Therapy Treat the Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (edit) |
|
第II相試験 (edit) |
NCT04299152 |
| Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) (edit) |
レムデシビル (edit) |
第III相試験 (edit) |
NCT04292899 |
| Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment (edit) |
レムデシビル (edit) |
第III相試験 (edit) |
NCT04292730 |
| The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19 (edit) |
|
第III相試験 (edit) |
NCT04291053 |
| The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19 (edit) |
|
第II相試験 (edit) |
NCT04291053 |
| Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19. (edit) |
一酸化窒素 (edit) |
第II相試験 (edit) |
NCT04290871 |
| Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection (edit) |
一酸化窒素 (edit) |
第II相試験 (edit) |
NCT04290858 |
| Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19) (edit) |
|
第II相試験 (edit) |
NCT04288102 |
| Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19) (edit) |
|
第I相試験 (edit) |
NCT04288102 |
| The Clinical Study of Carrimycin on Treatment Patients With COVID-19 (edit) |
クロロキン (edit) |
第IV相試験 (edit) |
NCT04286503 |
| The Clinical Study of Carrimycin on Treatment Patients With COVID-19 (edit) |
ロピナビル (edit) |
第IV相試験 (edit) |
NCT04286503 |
| The Clinical Study of Carrimycin on Treatment Patients With COVID-19 (edit) |
リトナビル (edit) |
第IV相試験 (edit) |
NCT04286503 |
| The Clinical Study of Carrimycin on Treatment Patients With COVID-19 (edit) |
Chloroquine diphosphate bearing dextran nanoparticles augmented drug delivery and overwhelmed drug resistance in Plasmodium falciparum parasites (edit) |
第IV相試験 (edit) |
NCT04286503 |
| Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) to Prevent SARS-CoV-2 Infection (edit) |
エラソメラン (edit) |
第I相試験 (edit) |
NCT04283461 |
| A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (edit) |
レムデシビル (edit) |
第III相試験 (edit) |
NCT04280705 |
| Fingolimod in COVID-19 (edit) |
fingolimod hydrochloride (edit) |
第II相試験 (edit) |
NCT04280588 |
| Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19 (edit) |
|
第III相試験 (edit) |
NCT04278963 |
| Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19 (edit) |
|
第II相試験 (edit) |
NCT04278963 |
| Function and Safety Study of SARS-CoV-2 Synthetic Minigene Vaccines (edit) |
|
第II相試験 (edit) |
NCT04276896 |
| Function and Safety Study of SARS-CoV-2 Synthetic Minigene Vaccines (edit) |
|
第I相試験 (edit) |
NCT04276896 |
| Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia (edit) |
ベバシズマブ (edit) |
第III相試験 (edit) |
NCT04275414 |
| Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia (edit) |
ベバシズマブ (edit) |
第II相試験 (edit) |
NCT04275414 |
| The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19 (edit) |
サリドマイド (edit) |
第II相試験 (edit) |
NCT04273581 |
| The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19 (edit) |
新型コロナウイルス感染症 (2019年) (edit) |
第II相試験 (edit) |
NCT04273581 |
| The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia (edit) |
サリドマイド (edit) |
第II相試験 (edit) |
NCT04273529 |
| Immunoregulatory Therapy for 2019-nCoV (edit) |
免疫グロブリン (edit) |
第II相試験 (edit) |
NCT04268537 |
| Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia (edit) |
アスコルビン酸 (edit) |
第II相試験 (edit) |
NCT04264533 |